ReviewDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2009
[Albumin eye drops for treatment of ocular surface diseases].
Review in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 18 citations in OpenAlex.
- [Corneal wound healing-Pharmacological treatment].Die Ophthalmologie · 2024Article
- Persistent Corneal Epithelial Defects: A Review Article.Medical hypothesis, discovery & innovation ophthalmology journal · 2019Review
- Review
- Human albumin eye drops as a therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allografting.Current oncology (Toronto, Ont.) · 2015Article
- Functional lacrimal gland regeneration by transplantation of a bioengineered organ germ.Nature communications · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For more than 10 years eye drops made from autologous serum have become an established therapy to support corneal wound healing in ocular surface diseases, such as persistent epithelial defects and dry eye. Serum eye drops can only be dispensed by institutions which have obtained a specific license from the appropriate local authorities and this applies to only a few institutes in Germany. The main protein component of serum is albumin which is commercially available as a quality controlled medical product from the pharmaceutical industry and could thus be used as an alternative to autologous serum eye drops. The wound healing effect of albumin eye drops has already been demonstrated in vitro. Here we outline the therapeutic principles and present our first clinical experiences with eye drops made from albumin in the treatment of ocular surface disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.